Study Number:	I10482B
Study Gender:	Both
PWG Approval Date:	See web page for date of PWG Approval
Version:	v1.3.2
Stat Version:	v2.7.2A

Study Number: I10482B
Test Type: TOX
Route: Dosing in Feed
Species/Strain: Rat/Harlan Sprague Dawley

PA46s: Summary of Gross Pathology
Test Compound: N-Butylbenzenesulfonamide
CAS Number: 3622-84-2

Date Report Requested: 09/15/2021
Time Report Requested: 07:36:35
Lab: Burleson Research Technologies

F0 Female

	Treatment Groups (ppm)			
	0	**250**	**500**	**1000**
Disposition Summary				
Animals Initially In Study	**30**	**30**	**30**	**30**
Censored				
Early Deaths				
Survivors				
Scheduled Sacrifice, Terminal	**30**	**29**	**30**	**29**
Number of Animals Examined	**29**	**29**	**29**	**29**
ALIMENTARY SYSTEM				
None				
CARDIOVASCULAR SYSTEM				
None				
ENDOCRINE SYSTEM				
None				
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
None				
HEMATOLYMPHOID SYSTEM				
None				
INTEGUMENTARY SYSTEM				
None				
MUSCULOSKELETAL SYSTEM				
None				

Study Number: I10482B
Test Type: TOX
Route: Dosing in Feed
Species/Strain: Rat/Harlan Sprague Dawley

PA46s: Summary of Gross Pathology
Test Compound: N-Butylbenzenesulfonamide
CAS Number: 3622-84-2

Date Report Requested: 09/15/2021
Time Report Requested: 07:36:35
Lab: Burleson Research Technologies

F0 Female

	Treatment Groups (ppm)			
	0	**250**	**500**	**1000**
NERVOUS SYSTEM				
None				
RESPIRATORY SYSTEM				
None				
SPECIAL SENSES SYSTEM				
None				
URINARY SYSTEM				
None				

F1 Male: SRBC

	Treatment Groups (ppm)				
	0	**250**	**500**	**1000**	**15 mg/kg CPS**
Disposition Summary					
Animals Initially In Study	**12**	**12**	**12**	**12**	**8**
Censored					
Early Deaths					
Survivors					
Scheduled Sacrifice, Terminal	**12**	**12**	**12**	**12**	**8**
Number of Animals Examined					
ALIMENTARY SYSTEM					
None					
CARDIOVASCULAR SYSTEM					
None					
ENDOCRINE SYSTEM					
None					
GENERAL BODY SYSTEM					
None					
GENITAL SYSTEM					
None					
HEMATOLYMPHOID SYSTEM					
None					
INTEGUMENTARY SYSTEM					
None					
MUSCULOSKELETAL SYSTEM					
None					

F1 Male: SRBC

	Treatment Groups (ppm)				
	0	**250**	**500**	**1000**	**15 mg/kg CPS**
NERVOUS SYSTEM					
None					
RESPIRATORY SYSTEM					
None					
SPECIAL SENSES SYSTEM					
None					
URINARY SYSTEM					
None					

F1 Female: SRBC

	Treatment Groups (ppm)				
	0	**250**	**500**	**1000**	**15 mg/kg CPS**
Disposition Summary					
Animals Initially In Study	**12**	**12**	**12**	**12**	**8**
Censored					
Early Deaths					
Sacrificed, Moribund				**1**	
Survivors					
Scheduled Sacrifice, Terminal	**12**	**12**	**12**	**11**	**8**
Number of Animals Examined				**1**	
ALIMENTARY SYSTEM					
INTESTINE, LARGE, CECUM	(0)	(0)	(0)	(1)	(0)
DISCOLORATION; GRAY				1 (100.0%)	
LIVER	(0)	(0)	(0)	(1)	(0)
DISCOLORATION; PALE				1 (100.0%)	
CARDIOVASCULAR SYSTEM					
None					
ENDOCRINE SYSTEM					
None					
GENERAL BODY SYSTEM					
CARCASS	(0)	(0)	(0)	(1)	(0)
HINDLIMB; SWELLING; FIRM, FLUID-FILLED				1 (100.0%)	
GENITAL SYSTEM					
None					
HEMATOLYMPHOID SYSTEM					
None					

F1 Female: SRBC

	Treatment Groups (ppm)				
	0	**250**	**500**	**1000**	**15 mg/kg CPS**
INTEGUMENTARY SYSTEM					
None					
MUSCULOSKELETAL SYSTEM					
None					
NERVOUS SYSTEM					
None					
RESPIRATORY SYSTEM					
None					
SPECIAL SENSES SYSTEM					
None					
URINARY SYSTEM					
KIDNEY	(0)	(0)	(0)	(1)	(0)
BILATERAL; DISCOLORATION; PALE				1 (100.0%)	

F1 Male: KLH

	Treatment Groups (ppm)				
	0	**250**	**500**	**1000**	**15 mg/kg CPS**
Disposition Summary					
Animals Initially In Study	**12**	**12**	**12**	**12**	**8**
Censored					
Early Deaths					
Survivors					
Scheduled Sacrifice, Terminal	**12**	**12**	**12**	**12**	**8**
Number of Animals Examined					
ALIMENTARY SYSTEM					
None					
CARDIOVASCULAR SYSTEM					
None					
ENDOCRINE SYSTEM					
None					
GENERAL BODY SYSTEM					
None					
GENITAL SYSTEM					
None					
HEMATOLYMPHOID SYSTEM					
None					
INTEGUMENTARY SYSTEM					
None					
MUSCULOSKELETAL SYSTEM					
None					

F1 Male: KLH

	Treatment Groups (ppm)				
	0	**250**	**500**	**1000**	**15 mg/kg CPS**
NERVOUS SYSTEM					
None					
RESPIRATORY SYSTEM					
None					
SPECIAL SENSES SYSTEM					
None					
URINARY SYSTEM					
None					

F1 Female: KLH

	Treatment Groups (ppm)				
	0	**250**	**500**	**1000**	**15 mg/kg CPS**
Disposition Summary					
Animals Initially In Study	**12**	**12**	**12**	**12**	**8**
Censored					
Early Deaths					
Survivors					
Scheduled Sacrifice, Terminal	**12**	**12**	**12**	**12**	**8**
Number of Animals Examined					
ALIMENTARY SYSTEM					
None					
CARDIOVASCULAR SYSTEM					
None					
ENDOCRINE SYSTEM					
None					
GENERAL BODY SYSTEM					
None					
GENITAL SYSTEM					
None					
HEMATOLYMPHOID SYSTEM					
None					
INTEGUMENTARY SYSTEM					
None					
MUSCULOSKELETAL SYSTEM					
None					

F1 Female: KLH

	Treatment Groups (ppm)				
	0	**250**	**500**	**1000**	**15 mg/kg CPS**
NERVOUS SYSTEM					
None					
RESPIRATORY SYSTEM					
None					
SPECIAL SENSES SYSTEM					
None					
URINARY SYSTEM					
None					

F1 Male: Immunophenotyping

	Treatment Groups (ppm)				
	0	**250**	**500**	**1000**	**15 mg/kg CPS**
Disposition Summary					
Animals Initially In Study	**12**	**12**	**12**	**12**	**8**
Censored					
Early Deaths					
Survivors					
Scheduled Sacrifice, Terminal	**12**	**12**	**11**	**12**	**8**
Number of Animals Examined					
ALIMENTARY SYSTEM					
None					
CARDIOVASCULAR SYSTEM					
None					
ENDOCRINE SYSTEM					
None					
GENERAL BODY SYSTEM					
None					
GENITAL SYSTEM					
None					
HEMATOLYMPHOID SYSTEM					
None					
INTEGUMENTARY SYSTEM					
None					
MUSCULOSKELETAL SYSTEM					
None					

F1 Male: Immunophenotyping

	Treatment Groups (ppm)				
	0	**250**	**500**	**1000**	**15 mg/kg CPS**
NERVOUS SYSTEM					
None					
RESPIRATORY SYSTEM					
None					
SPECIAL SENSES SYSTEM					
None					
URINARY SYSTEM					
None					

F1 Female: Immunophenotyping

	Treatment Groups (ppm)				
	0	**250**	**500**	**1000**	**15 mg/kg CPS**
Disposition Summary					
Animals Initially In Study	**12**	**12**	**12**	**12**	**8**
Censored					
Early Deaths					
Survivors					
Scheduled Sacrifice, Terminal	**12**	**12**	**12**	**12**	**8**
Number of Animals Examined					
ALIMENTARY SYSTEM					
None					
CARDIOVASCULAR SYSTEM					
None					
ENDOCRINE SYSTEM					
None					
GENERAL BODY SYSTEM					
None					
GENITAL SYSTEM					
None					
HEMATOLYMPHOID SYSTEM					
None					
INTEGUMENTARY SYSTEM					
None					
MUSCULOSKELETAL SYSTEM					
None					

F1 Female: Immunophenotyping

	Treatment Groups (ppm)				
	0	**250**	**500**	**1000**	**15 mg/kg CPS**
NERVOUS SYSTEM					
None					
RESPIRATORY SYSTEM					
None					
SPECIAL SENSES SYSTEM					
None					
URINARY SYSTEM					
None					

F1 Male: CTL

	Treatment Groups (ppm)				
	0	**250**	**500**	**1000**	**15 mg/kg CPS**
Disposition Summary					
Animals Initially In Study	**12**	**12**	**12**	**12**	**8**
Censored		**1**			
Early Deaths					
Survivors					
Scheduled Sacrifice, Terminal	**12**	**11**	**12**	**12**	**8**
Number of Animals Examined		**1**			
ALIMENTARY SYSTEM					
None					
CARDIOVASCULAR SYSTEM					
None					
ENDOCRINE SYSTEM					
None					
GENERAL BODY SYSTEM					
None					
GENITAL SYSTEM					
None					
HEMATOLYMPHOID SYSTEM					
None					
INTEGUMENTARY SYSTEM					
None					
MUSCULOSKELETAL SYSTEM					
None					

F1 Male: CTL

	Treatment Groups (ppm)				
	0	**250**	**500**	**1000**	**15 mg/kg CPS**
NERVOUS SYSTEM					
None					
RESPIRATORY SYSTEM					
None					
SPECIAL SENSES SYSTEM					
None					
URINARY SYSTEM					
None					

F1 Female: CTL

	Treatment Groups (ppm)				
	0	**250**	**500**	**1000**	**15 mg/kg CPS**
Disposition Summary					
Animals Initially In Study	**12**	**12**	**12**	**12**	**8**
Censored					
Early Deaths					
Found Dead					**1**
Survivors					
Scheduled Sacrifice, Terminal	**12**	**12**	**12**	**12**	**7**
Number of Animals Examined					
ALIMENTARY SYSTEM					
None					
CARDIOVASCULAR SYSTEM					
None					
ENDOCRINE SYSTEM					
None					
GENERAL BODY SYSTEM					
None					
GENITAL SYSTEM					
None					
HEMATOLYMPHOID SYSTEM					
None					
INTEGUMENTARY SYSTEM					
None					

F1 Female: CTL

	Treatment Groups (ppm)				
	0	**250**	**500**	**1000**	**15 mg/kg CPS**
MUSCULOSKELETAL SYSTEM					
None					
NERVOUS SYSTEM					
None					
RESPIRATORY SYSTEM					
None					
SPECIAL SENSES SYSTEM					
None					
URINARY SYSTEM					
None					

F1 Male: Immunopathology

	Treatment Groups (ppm)				
	0	**250**	**500**	**1000**	**15 mg/kg CPS**
Disposition Summary					
Animals Initially In Study	**12**	**12**	**12**	**12**	**8**
Censored					
Early Deaths					
Found Dead		**1**			
Survivors					
Scheduled Sacrifice, Terminal	**12**	**11**	**12**	**12**	**8**
Number of Animals Examined	**12**	**11**	**12**	**12**	**8**
ALIMENTARY SYSTEM					
None					
CARDIOVASCULAR SYSTEM					
None					
ENDOCRINE SYSTEM					
ADRENAL GLAND, RIGHT	(12)	(11)	(12)	(12)	(0)
SMALL; MODERATE		1 (9.1%)			
GENERAL BODY SYSTEM					
None					
GENITAL SYSTEM					
None					

F1 Male: Immunopathology

	Treatment Groups (ppm)				
	0	**250**	**500**	**1000**	**15 mg/kg CPS**
HEMATOLYMPHOID SYSTEM					
LYMPH NODE, POPLITEAL	(12)	(11)	(12)	(12)	(8)
DISCOLORATION; BLACK, MODERATE	11 (91.7%)	7 (63.6%)	7 (58.3%)	5 (41.7%)	
DISCOLORATION; MODERATE		1 (9.1%)			
SPLEEN	(0)	(0)	(0)	(0)	(8)
SMALL; MILD					2 (25.0%)
THYMUS	(12)	(11)	(12)	(12)	(8)
SMALL; MARKED	0				5 (62.5%) **
SMALL; MINIMAL		1 (9.1%)	2 (16.7%)	1 (8.3%)	
SMALL; MODERATE	0				3 (37.5%) *
INTEGUMENTARY SYSTEM					
None					
MUSCULOSKELETAL SYSTEM					
None					
NERVOUS SYSTEM					
None					
RESPIRATORY SYSTEM					
None					
SPECIAL SENSES SYSTEM					
None					
URINARY SYSTEM					
None					

F1 Female: Immunopathology

	Treatment Groups (ppm)				
	0	**250**	**500**	**1000**	**15 mg/kg CPS**
Disposition Summary					
Animals Initially In Study	**12**	**12**	**12**	**12**	**8**
Censored					
Early Deaths					
Survivors					
Scheduled Sacrifice, Terminal	**12**	**12**	**12**	**12**	**8**
Number of Animals Examined	**12**	**12**	**12**	**12**	**8**
ALIMENTARY SYSTEM					
LIVER	(12)	(12)	(12)	(12)	(0)
ENLARGED; MILD		1 (8.3%)			
MASS; MOTTLED		1 (8.3%)			
MASS				1 (8.3%)	
CARDIOVASCULAR SYSTEM					
None					
ENDOCRINE SYSTEM					
None					
GENERAL BODY SYSTEM					
None					
GENITAL SYSTEM					
None					

F1 Female: Immunopathology

	Treatment Groups (ppm)				
	0	**250**	**500**	**1000**	**15 mg/kg CPS**
HEMATOLYMPHOID SYSTEM					
LYMPH NODE, POPLITEAL	(12)	(12)	(12)	(12)	(8)
DISCOLORATION; BLACK, MODERATE	10 (83.3%)	9 (75.0%)	8 (66.7%)	2 (16.7%)	
DISCOLORATION; MODERATE			1 (8.3%)		
SPLEEN	(12)	(12)	(12)	(12)	(8)
NODULE; PROXIMAL		1 (8.3%)			
SMALL; MILD	0				5 (62.5%) **
THYMUS	(12)	(12)	(12)	(12)	(8)
SMALL; MARKED					2 (25.0%)
SMALL; MILD				1 (8.3%)	
SMALL; MODERATE	0				6 (75.0%) **
INTEGUMENTARY SYSTEM					
SKIN	(12)	(12)	(12)	(12)	(8)
DISCOLORATION; BLACK, MODERATE	1 (8.3%)				
MUSCULOSKELETAL SYSTEM					
None					
NERVOUS SYSTEM					
None					
RESPIRATORY SYSTEM					
None					
SPECIAL SENSES SYSTEM					
None					
URINARY SYSTEM					
None					

LEGEND

Censored animals are scheduled for sacrifice prior to the end of the study. The censored animals are included in the pathology data.

Number of animals examined for each tissue shown in parentheses. If none of the animals examined have the specific lesion then there is a blank for that dose group for that specific lesion. The exception to this is if statistical significance is found for a lesion and the control group has no animals with the lesion then a 0 is included for the control group on the table for that lesion.

Number (percent) of animals affected given for each observation

Statistical analysis performed by Cochran-Armitage (trend) and Fisher Exact (pairwise) one-sided tests.

Statistical analysis for the positive control group compared to the vehicle control group was performed using the Fisher Exact test.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at P <= 0.05

** Statistically significant at P <= 0.01

CPS = Cyclophosphamide

** END OF REPORT **